• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
Vishal Doshi, AUM Biosciences CEO
October 20, 2022 10:51 AM EDT
Financing
Startups
Deals

Play­boy, dig­i­tal health, elec­tric ve­hi­cles and now can­cer drugs: A moun­tain­ous SPAC jour­ney

Kyle LaHucik

Biotech Correspondent

A pro­lif­ic SPAC cre­ator has found a busi­ness part­ner for its fifth blank check com­pa­ny with just four weeks to go be­fore a busi­ness com­bi­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • Sage talked to 43 'coun­ter­par­ties' be­fore ink­ing Su­per­nus deal July 3, 2025
  • Sh­iono­gi, BioVer­sys team up on an­tibi­otics for lung dis­ease in deal worth up to $614M July 2, 2025
  • Ex­clu­sive: VC firm lines up $200M fund to cham­pi­on Japan­ese in­no­va­tion July 1, 2025
TRENDING NOW

Chi­na’s rise splits US biotech in­vestors: Cash in, or counter? 

Num­ber of megarounds drops 38% in first half as biotechs strug­gle against wors­en­ing slump

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

Ap­ple Tree says its biotechs face ‘im­mi­nent col­lapse’; Ad­vo­cates urge J&J to pro­ceed with eye gene ther­a­py; ...

Roche-backed Chugai taps in­to longevi­ty field with Pfiz­er-al­lied Gero

Now pri­vate, blue­bird bio con­tin­ues lead­er­ship re­vamp; Roche R&D ex­ec an­nounces re­tire­ment

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times